January 16, 2026 a 09:00 pm
PFE: Analysts Ratings - Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical company, renowned for its rich pipeline of vaccines and medicines. Despite a challenging market landscape influenced by the pandemic and changing healthcare policies, Pfizer has maintained a robust portfolio and strategic collaborations. Continuous innovation in sectors like immunotherapy and vaccine development positions Pfizer well for sustained growth. Analyst ratings reflect a cautious but generally optimistic sentiment towards Pfizer's stock.
Historical Stock Grades
The analyst ratings for Pfizer Inc. have remained relatively stable over the past several months, with a noticeable emphasis on 'Hold' recommendations. This suggests a cautious optimism about the company's performance in light of ongoing market conditions. There have been minimal changes in 'Buy' and 'Strong Buy' categories, indicating a more conservative market sentiment.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 7 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment around Pfizer Inc. has exhibited some shifts over recent months. A consistency in 'Hold' recommendations suggests a balanced view towards the stock. However, the sparse 'Strong Sell' designation indicates that analysts perceive limited downside risk currently.
- Recent months demonstrate resilience in 'Hold' ratings, supporting a neutral outlook.
- 'Strong Buy' ratings reflect a degree of confidence in the stock's long-term potential, though a slight decrease was noted.
- The data shows a steady overall count in analyst opinions, indicating stability in sentiment.
Percentage Trends
Analyzing the percentage trends over the last year reveals a noteworthy tilt towards caution among analysts. While there are consistent 'Buy' ratings, the 'Hold' category has notably increased, signifying a watchful approach.
- Shift towards 'Hold' recommendations indicates more conservative viewpoints among analysts.
- Decrease in 'Strong Buy' percentages points to lowered immediate growth expectations.
- The weight of 'Buy' and 'Hold' categories remains predominant, reflecting balanced sentiment.
- In the last six months, increased caution is evident, with a decrease in 'Strong Buy' ratings and a stable 'Hold'.
Latest Analyst Recommendations
Recent analyst recommendations for Pfizer have shown a steady line of 'Equal Weight' and 'Neutral' ratings by top analysts, indicating consensus on Pfizer's market position.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-17 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-12-15 | Neutral | Neutral | B of A Securities |
| 2025-12-12 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-11-24 | Buy | Buy | Guggenheim |
| 2025-10-10 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
The table below highlights significant changes in analyst opinions, reflecting strategic realignments in perceptions of Pfizer's stock performance.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-08-08 | Outperform | Neutral | Daiwa Capital |
| 2024-03-22 | Hold | Buy | Argus Research |
| 2024-01-04 | Market Perform | Outperform | TD Cowen |
| 2023-10-16 | Buy | Hold | Jefferies |
Interpretation
The analysis of Pfizer Inc.'s stock ratings over time suggests a cautious yet optimistic outlook. While the increase in 'Hold' ratings suggests some hesitance, the maintenance of 'Buy' recommendations indicates confidence in Pfizer's strategic initiatives. The consistent lack of 'Strong Sell' recommendations underlines perceived stability, albeit with a prudent stance.
Conclusion
Pfizer Inc.'s analyst ratings illustrate a balanced sentiment with an inclination towards caution. While 'Hold' recommendations have risen, a stable presence of 'Buy' ratings provides an optimistic undertone about expected performance. With a robust pipeline and significant market share in the biopharmaceutical sector, Pfizer appears well-positioned despite market uncertainties. However, investors should remain vigilant about shifts in analyst enthusiasm and broader market conditions, which could influence future ratings.